Add-on Acquisition • Life Science

Accord Healthcare Acquires Prothya Biosolutions

On October 20, 2025, Accord Healthcare acquired life science company Prothya Biosolutions from Fortissimo Capital

Acquisition Context
  • This is Accord Healthcare’s 1st transaction in the Life Science sector.
  • This is Accord Healthcare’s 1st transaction in Belgium.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free


M&A Deal Summary

Date October 20, 2025
Target Prothya Biosolutions
Sector Life Science
Buyer(s) Accord Healthcare
Sellers(s) Fortissimo Capital
Deal Type Add-on Acquisition

Target Company

Prothya Biosolutions

Brussels, Belgium
Prothya Biosolutions produces and exports a broad range of pharmaceuticals for patients throughout the world. Prothya Biosolutions is based in Brussels, Belgium.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Accord Healthcare

London, United Kingdom

Category Company
Sector Life Science
DESCRIPTION

Accord Healthcare Ltd. is a generic pharmaceutical in the United States, per IMS Health. It has 14 manufacturing locations across the globe and employs over 14,000 people. Accord has FDA approval for 76 oral and injectable drug products in the U.S., and over 180 drug submissions either pending at FDA or in active development.


Deal Context for Buyer #
Overall 2 of 2
Sector: Life Science 1 of 1
Type: Add-on Acquisition 2 of 2
Country: Belgium 1 of 1
Year: 2025 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-07-26 Essential Pharmaceuticals

Ewing, New Jersey, United States

Essential Pharmaceuticals LLC is a provider of medical products to surgeons, bio pharmaceutical companies and research facilities. Essential Pharmaceuticals was founded in 2006 and is based in Ewing, New Jersey.

Buy -

Seller Profile 1

SELLER

Fortissimo Capital

Tel Aviv, Israel

Investor Investor Investor Investor Investor


Category Growth Capital Firm
Founded 2004
PE ASSETS 2.7B USD
Size Large
Type Sector Agnostic
DESCRIPTION

Fortissimo Capital is a private equity firm that targets investments in private and public Israeli companies. The Firm looks to invest in technology-based and industrial companies that require capital to expand. Fortissimo focuses on companies operating in high growth markets with proven sales, consistent revenue streams, and strong customer bases. Fortissimo will consider a variety of transaction situations including spinouts, selling shareholders, growth capital financings, and special situations. Fortissimo Capital was formed in 2004 and is based in Tel Aviv.


Deal Context for Seller #
Overall 14 of 14
Sector: Life Science 2 of 2
Type: Add-on Acquisition 8 of 8
Country: Belgium 1 of 1
Year: 2025 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-12-22 Morning

Tel Aviv, Israel

Morning focuses developing an entire ecosystem, based on advanced technologies, aiming to provide a solution for most needs and challenges of freelancers and small businesses. Small and medium businesses make up the bulk of its clientele, but it also service local large companies such as Hamashbir Lazarchan, BuyMe, Max Brener, Gottex, and ShookIt. Morning was formed in 2011 and is based in Tel Aviv, Israel.

Sell -